Immix Biopharma Inc (IMMX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immix Biopharma Inc (IMMX) has a cash flow conversion efficiency ratio of -0.715x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.91 Million) by net assets ($8.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immix Biopharma Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Immix Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Immix Biopharma Inc (IMMX) total liabilities for a breakdown of total debt and financial obligations.
Immix Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immix Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Canaan Technology Co Ltd
SHE:300412
|
0.074x |
|
Yangzhou Chenhua New Material Co Ltd
SHE:300610
|
-0.012x |
|
Berto Acquisition Corp. Ordinary Shares
NASDAQ:TACO
|
0.000x |
|
Bankwell Financial Group Inc
NASDAQ:BWFG
|
0.034x |
|
Invesco Advantage MIT II
NYSE MKT:VKI
|
0.022x |
|
Malaysia Smelting Corporation Bhd
KLSE:5916
|
0.133x |
|
Kopin Corporation
NASDAQ:KOPN
|
-0.005x |
|
Rapac Communication & Infrastructure Ltd
TA:RPAC
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Immix Biopharma Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Immix Biopharma Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see IMMX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.25 Million | $-14.60 Million | -1.101x | -56.94% |
| 2023-12-31 | $16.20 Million | $-11.37 Million | -0.702x | -24.66% |
| 2022-12-31 | $13.16 Million | $-7.41 Million | -0.563x | -537.23% |
| 2021-12-31 | $17.99 Million | $-1.59 Million | -0.088x | -203.27% |
| 2020-12-31 | $-4.73 Million | $-404.69K | 0.086x | -60.52% |
| 2019-12-31 | $-3.65 Million | $-790.03K | 0.217x | -- |
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1… Read more